Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.55 |
| ▸ | DPP4 | P27487 | 4/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545180 | 0.82 | CNR2 (1.00) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL16938168 | 0.81 | DPP9 (0.47) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL30685074 | 0.77 | DPP9 (0.78) | DPP9DPP8DPP4 | |
| SCHEMBL15545110 | 0.75 | CNR2 (0.69) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL15546058 | 0.74 | CNR2 (1.00) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL6975690 | 0.73 | HSD11B1 (0.70) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR | |
| SCHEMBL3660060 | 0.73 | DPP9 (0.58) | DPP9DPP8DPP4DPP7 | |
| SCHEMBL30685001 | 0.73 | DPP9 (1.00) | DPP9DPP8 | |
| SCHEMBL27356261 | 0.73 | DPP9 (1.00) | DPP9DPP8 | |
| SCHEMBL15544757 | 0.72 | HSD11B1 (1.00) | CNR2ALDH1A1SMN1; SMN2NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | claimed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| EP-2870139-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | claimed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | claimed |
| WO-2014005968-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | claimed |
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2870139-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2014005968-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR1, CNR2, GPR18 | CNR2 2/4885ALDH1A1 889/4885SMN1; SMN2 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.